Researchers aim to over-stress already taxed mantle cell lymphoma cells

...y of heat shock protein 90. "Cancer cells require hsp90 for keeping their proteins in active conformation ...gia Cancer Coalition Distinguished Cancer Scholar. hsp90 is one of the more common molecular chaperones, wh...stress on the endoplasmic reticulum. Independently hsp90 inhibitors are known to selectively kill cancer ce...

Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators

...rancisco, California, is investigating the molecular mechanism by which the hsp90 protein chaperone affects the folding of substrate proteins. The effect of hsp90 on folding is important because this chaperone activates a wide variety of ...

HSP90: New point of view on melanoma of the eye, at the MUHC

...we had to target Heat Shock Protein 90 (HSP90). hsp90 is already a therapeutic target in many other type...e effectiveness of an antibiotic called 17/AAG, an hsp90 inhibitor, against malignant tumours of the skin, ...ell lines. Our results clearly prove not only that hsp90 is largely overexpressed in this type of tumour bu...

Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma

... Kosan Leads Industry with Most Advanced hsp90 Inhibitor in Clinical ... in patients with less advanced disease. Kosan's hsp90 and Epothilone Clinical Programs on Track for 2008...to entering the trial. Kosan's second-generation hsp90 inhibitor, alvespimycin, has demonstrated encourag...

Cancer cell line developed that is resistant to new cancer therapy

...e mechanisms, they acquired greater sensitivity to hsp90 inhibitors, says Dr. Bhalla, Cecil F. Whitaker Jr....models and ultimately clinical trials. HDAC and hsp90 inhibitors are both being studied in combination w...dies also are underway for some innovative uses of hsp90 inhibitors, including Dr. John Catravas studies of...

Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results

... anticancer agents through clinical development -- hsp90 (heat shock protein 90) inhibitors and epothilones...ct candidates, primarily in the area of oncology. hsp90 inhibitors have a novel mechanism of action target...and oral formulations of Kosan's second-generation hsp90 inhibitor, alvespimycin (KOS-1022), are being eval...

Scientists Discover Prostate Cancer Triggering Molecule

...eldanamycin inhibited Ack1 through interference with its molecular interactions, 'If you add geldanamycin to the prostate cancer cell, the drug knocks hsp90 off oncogenic signaling molecules. This dramatically decreases Ack1 activity and slows tumor formation,' Earp added. The team also found that Ack1 lev...

Gene responsible for developing prostate cancer identified

... treatment. First, the group discovered that Ack1 bound to a protein called hsp90 (heat shock protein 90), which associated with many oncogenic, or cancer-ca... 'If you add geldanamycin to the prostate cancer cell, the drug knocks hsp90 off oncogenic signaling molecules. This dramatically decreases Ack1 activit...

Hsp90 in Medical Technology

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

Data Presented at ASCO Show 26% Partial Response, 63% Clinical Benefit Incidence HAYWARD, Calif., June 3 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that its lead Hsp90 inhibitor, tanespimycin, demonstrated a high lev...

Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer

HAYWARD, Calif., Jan. 15 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced the initiation of a Phase 2 trial of alvespimycin, the company's second-generation Hsp90 inhibitor, in patients with HER2-positive metastatic breast cancer. Alvespimycin has demon...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

HAYWARD, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) presented updated data from a dose-escalating Phase 1b clinical trial of Hsp90 inhibitor tanespimycin (KOS-953) in combination with bortezomib (Velcade(R)), showing durable antitumor activity and ...

First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs

HWI Scientist Dr. Dan Gewirth's Groundbreaking Research Makes Cover of Molecular Cell BUFFALO, N.Y., Oct. 19 /PRNewswire/ -- Dr. Dan Gewirth, Hauptman-Woodward senior research scientist, has just solved the structure of the first mammalian GRP94 protein implicated ...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

Data Presented at ASCO Breast Cancer Symposium; Additional Positive Results Seen Since Presentation at ASCO Annual Meeting in June Phase I Trial Expanding to Include Alvespimycin Plus Trastuzumab Plus Paclitaxel Regimen HAYWARD, Calif., Sept. 10 /PRNewswire-F...

Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma

Tanespimycin is Industry's First Hsp90 Inhibitor to Enter Registration Program TIME Registration Program Utilizes New, Proprietary Tanespimycin Formulation HAYWARD, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorp...

Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR

Tanespimycin Shown to Have No Effect on QTc Interval HAYWARD, Calif., April 16, 2007 /PRNewswire/ -- Kosan Biosciences Incorporated today presented safety data from preclinical and clinical studies of its lead Hsp90 inhibitor, tanespimycin (KOS-953). Serial electrocardiogram (ECG) monitoring of pa...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented preliminary data from a Phase 2 monotherapy trial showing that tanespimycin demonstrated antitumor activity and tolerability in patients with metastatic melanoma, including one patient with a BRAF mut...

Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO

Tanespimycin TIME Registration Program to Begin Third Quarter 2007 HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a dose-escalating Phase 1b clinical trial of its lead Hsp90 inhibitor, tanespimycin (KOS-953) in combination with bortezomi...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...dynamics and pharmacokinetics of AUY922 in a Phase I study of solid tumor patients These data support the use of HSP70 as a biomarker for hsp90 inhibition. Inhibition of HSP90, a key target that regulates tumor cell survival and division, through the use of AUY922, resulted in an up regulation...

Hsp90 in Biological News

First high-res 3D structures of mammalian HSP90 protein solved

Dr. Dan Gewirth, Hauptman-Woodward senior research scientist, has just solved the structure of the first mammalian GRP94 protein implicated in immune diseases such as sepsis, AIDS and certain cancers. His work is being published today in a cover article in a top scientific journal - Molecular Cel...

Targeting helpers of heat shock proteins could help treat cancer, cardiovascular disease

...searchers say. "We are trying to understand how hsp90 folds steroid receptors into the proper conformati...h their function when they are helping cancer." hsp90 is vital to steroid receptors whether they are inv... with normal hormonal function or cancer. Vital to hsp90 are helpers such as p23 that help it dock at the r...

Sidestepping cancer's chaperone

...Mitochondrial Homeostasis by an Organelle-Specific hsp90 Chaperone Network, published in the October 19 iss...agues sought to both define the mechanism by which hsp90 leads to tumor cell stability and survival, and understand why general suppression of hsp90 has not been as successful in clinical trials. ...

Scripps research study shows humans and plants share common regulatory pathway

...ys to accomplish related biological responses." The study also showed that a heat shock protein, HSP90, helped stabilize Nod1. "Inhibiting hsp90 resulted in a significant reduction of Nod1 protein levels," Ulevitch said. "That clearly suggests that this protein plays a key role in stabilizing N...

Researchers find docking sites for glucocorticoid receptor and Hsp90

...tions of a heat-shock protein known as Hsp90. hsp90 belongs to a family of proteins called chaperones ...ntain their 3-D structure. Unlike most chaperones, hsp90 is dedicated to assist a restricted yet diverse gr... glucocorticoid receptor, which requires help from hsp90 to interact with hormones. Scientists had been sty...

FDA approves more generic AIDS drugs

...thers believed that the proteins -- RAR1, SGT1 and hsp90 -- were required for what is called signal transdu... defense response," Holt said. "The proteins RAR1, hsp90 and SGT1 were previously thought to work together ...why they antagonized each other, he said. RAR1 and hsp90 can prevent resistance proteins from disappearing,...

UNC plant researchers discover proteins interact to form hair-trigger protection against invaders

...thers believed that the proteins -- RAR1, SGT1 and hsp90 -- were required for what is called signal transdu... defense response," Holt said. "The proteins RAR1, hsp90 and SGT1 were previously thought to work together ...why they antagonized each other, he said. RAR1 and hsp90 can prevent resistance proteins from disappearing,...

While on trail of dioxin, scientists pinpoint cancer target of green tea

...tlake discovered that a chaperone protein known as hsp90 is involved in conferring green tea's protective e...many cancer cells have an increase in the level of hsp90 compared to healthy cells, and that when hsp90 is blocked, levels of proteins that make cancer ce...

Hsp90 in Biological Technology

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

CAMBRIDGE, Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS ), a drug development company focused on developing proprietary targeted medicines for cancer treatment and Debiopharm Group (Debiopharm), a group of companies with a focus on the developme...

Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR

HAYWARD, Calif., April 16 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) presented data on its novel, proprietary third-generation Hsp90 inhibitors demonstrating a high degree of target specificity, strong binding affinity and potency, a long lifetime in tumor tissue...

Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer

Five of 20 Evaluable Patients Had Confirmed Partial Responses (25%); Updated Data Presented at San Antonio Breast Cancer Symposium HAYWARD, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that its Hsp90 inhibitor, tanespimycin, de...

NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors

Company to develop for treatment of neurofibromatosis and cancer NEW YORK, Sept. 26 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc., a privately held New York biotechnology company focused on developing drugs to treat the genetic disorder neurofibromatosis and related sporadic tumo...

Assay Designs(TM), Inc. Announces Release of First Available Product for Multiplex Analysis of Heat Shock Proteins

...y enables measurement of HSP client proteins (Akt and Akt phosphor-Ser473) and HSPs (Hsp27 phospho Ser15, Hsp27 phospho-Ser82, Hsp40, Hsp60, Hsp70 and hsp90 alpha) in cell lysates. The assay utilizes monoclonal antibodies or antigen affinity purified polyclonal antibodies covalently coupled to latex beads....

Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer

...be of significant value to Kosan as we advance our hsp90 inhibitor and epothilone programs through later st...nticancer agents through clinical development -- a hsp90 (heat shock protein 90) inhibitor and an epothilone. hsp90 inhibitors have a novel mechanism of action target...

Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference

...cing two new classes of anticancer agents through clinical development -- a hsp90 (heat shock protein 90) inhibitor and an epothilone. hsp90 inhibitors have a novel mechanism of action targeting multiple pathways inv...

Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC)

...ve forward with research investigating the role of hsp90 in the progression of many cancers. "I am excited ... prospect of utilizing this antibody to target the hsp90 chaperone and to potentially curtail the metastati...tool to explore the role of cell surface localized hsp90 protein in cancer progression. Since this antibody...

Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results

...cing two new classes of anticancer agents through clinical development -- a hsp90 (heat shock protein 90) inhibitor and an epothilone. hsp90 inhibitors have a novel mechanism of action targeting multiple pathways inv...

NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect

...-- NexGenix Pharmaceuticals, presented data on its hsp90 inhibitor program today at the Annual Meeting of t...eutic window compared to 17AAG, the first-in-class hsp90 inhibitor currently in Phase 2 clinical trials for cancer. The compound series appears to bind hsp90 in a different mode than 17AAG or radicicol and ex...

Hsp90 in Biological Products

Anti-Heat Shock Protein 75 (hsp75) (TRAP-1) Ab-2 Monoclonal Antibody, Unconjugated from Lab Vision

Description:... (HSPs), more appropriately called as stress response proteins (SRPs). The hsp90 family of proteins in mammalian cells consists of hsp90 alpha and beta, Grp94, and Trap-1 (Hsp75). It was found that human TRAP-1 i...
Company:Lab Vision